# A Study With Darapladib to Collect Tolerability Information

> **NCT00704431** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 2 (actual)

## Conditions studied

- Atherosclerosis

## Interventions

- **DRUG:** SB-480848 (darapladib)

## Key facts

- **NCT ID:** NCT00704431
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-05
- **Primary completion:** 2008-10
- **Final completion:** 2008-10
- **Target enrollment:** 2 (ACTUAL)
- **Last updated:** 2016-11-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00704431

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00704431, "A Study With Darapladib to Collect Tolerability Information". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT00704431. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*